CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
red blood cell transfusionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02465125
NCT02465125Phase 2Completed

The Transfusion Triggers in Vascular Surgery Trial: Two Different Transfusion Triggers for Postoperative Haemoglobin Separation and Adherence to Transfusion Strategies in Vascular Surgery: a Randomised Clinical Feasibility Trial

Naestved Hospital·interventional·Posted Jun 8, 2015·Updated Jul 25, 2017

In Brief

A Phase 2 clinical trial evaluating red blood cell transfusion for Atherosclerosis and 3 related conditions. Completed, enrolled 58 participants across 1 site.

Detailed Summary

BACKGROUND * Vascular surgical patients often receive red blood cell (RBC) transfusions in the peri-operative period * RBC transfusion may lead to improved outcome but on the other hand the intervention may be harmful * Danish Health and Medicines Authority recommends transfusion of RBC at hemoglobin below 5 mmol/L while local clinical guidelines recommend transfusion of RBC to maintain hemoglobin levels above 6 mmol/L * A large randomized clinical trial is needed to evaluate the efficacy and safety of RBC transfusion in patients undergoing vascular surgery. * A trial examining the effect of RBC transfusion on tissue oxygenation is used to test the trial-design and feasibility for a trial evaluating post-operative mortality and morbidity.

Study Details

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 8, 2015
Enrollment StartJul 15, 2015
Primary CompletionDec 8, 2016
Study CompletionJan 9, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.1 years ago

Interventions

red blood cell transfusionbiological